September 2023 in “International Journal of Trichology” Tofacitinib helped a woman regrow hair with no major side effects.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
56 citations
,
July 2014 in “PloS one” SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
January 2026 in “Journal of Applied Pharmaceutical Science” Selaginella doederleinii extract shows potential for cervical cancer treatment but needs more research.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
4 citations
,
January 2022 in “Dermatologic Therapy” Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
May 2026 in “Journal of Dermatological Treatment” Patients with alopecia areata prefer treatments that regrow scalp hair quickly over how often they need to take the medication.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
29 citations
,
April 2019 in “Acta neuropathologica communications” Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.
June 2023 in “British journal of dermatology/British journal of dermatology, Supplement” Patients with alopecia areata face challenges accessing Janus kinase inhibitors, but some see positive results.
August 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” The model successfully predicted new uses for existing drugs, like using certain hormonal and heart medications for respiratory and Parkinson's diseases, and a cancer drug for diabetes.
12 citations
,
December 2010 in “Journal of thoracic oncology” New treatments for non-small cell lung cancer are being tested, with some already in use, focusing on immune response and targeting cancer cells, but side effects vary.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
Suppressing ODC activity reduces tumor growth in hair follicles.
1 citations
,
December 2024 in “Archives of Iranian Medicine” Tofacitinib may help treat Lichen Planopilaris, but more research is needed.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
96 citations
,
December 2015 in “JAMA dermatology” Topical Ruxolitinib may safely treat severe hair loss.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
February 2026 in “Advanced Science” TTNPB helps turn stem cells into neural stem cells, improving depression-like behaviors in rats.
The treatment was not recommended due to limited effectiveness and significant side effects.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
November 2025 in “Eurasian journal of applied biotechnology” Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
26 citations
,
July 2007 in “Biochemical Pharmacology” ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
13 citations
,
June 2023 in “Frontiers in Pharmacology” Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.
8 citations
,
June 2022 in “Cancers” Epirubicin and cyclophosphamide cause more anemia and side effects than docetaxel and cyclophosphamide, but both are equally effective.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.